Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis

Diabetes

Volumn 57, Issue 5, 2008, Pages 1355-1362

  Valenti, Luca ^a   Rametta, Raffaela ^a   Dongiovanni, Paola ^a   Maggioni, Marco ^b   Fracanzani, Anna Ludovica ^a   Zappa, Marco ^a   Lattuada, Enzo ^a   Roviaro, Giancarlo ^a   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b University Hospital San Paolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATASE; INSULIN; MESSENGER RNA; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHOPYRUVATE CARBOXYLASE; PROTEIN KINASE B; SERINE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIPOGENESIS; LIVER; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MODULATION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SCORING SYSTEM; AGED; BIOPSY; GENETICS; GLUCONEOGENESIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOPSY; FATTY LIVER; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUCONEOGENESIS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; OXIDATIVE STRESS; RNA, MESSENGER;

EID: 45749114635     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0714     Document Type: Article

References (42)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395, 2004
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850, 2001
3. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325-1330, 2006
4. Day CP: From fat to inflammation. Gastroenterology 130:207-210, 2006
5. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM: Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 54:3140-3147, 2005
6. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K: Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41:64-71, 2005
7. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873, 2006
8. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113-121, 2005
9. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48:1684-1699, 2005
10. Valenti L, Pulixi E, Fracanzani AL, Dongiovanni P, Maggioni M, Orsatti A, Gianni C, Fargion S: TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 43:944-950, 2005
11. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI: Mechanism ofhepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353, 2004
12. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI: Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117:739-745, 2007
13. Nakae J, Biggs WH 3rd, Kitamura T, Cavenee WK, Wright CV, Arden KC, Accili D: Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32:245-253, 2002
14. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D: Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab 6:208-216, 2007
15. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, Spiegelman BM: Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423:550-555, 2003
16. Sekine K, Chen YR, Kojima N, Ogata K, Fukamizu A, Miyajima A: Foxo1 links insulin signaling to C/EBPalpha and regulates gluconeogenesis during liver development. Embo J, 2007
17. Duong DT, Waltner-Law ME, Sears R, Sealy L, Granner DK: Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcrip-tional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxy-kinase gene promoter. J Biol Chem 277:32234-32242, 2002
18. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM: Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55:2042-2050, 2006
19. Frescas D, Valenti L, Accili D: Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280:20589-20595, 2005
20. Nakae J, Cao Y, Daitoku H, Fukamizu A, Ogawa W, Yano Y, Hayashi Y: The LXXLL motif of murine forkhead transcription factor FoxO1 mediates Sirt1-dependent transcriptional activity. J Clin Invest 116:2473-2483, 2006
21. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082-1090, 2005
22. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307, 2006
23. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470, 1999
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421, 2002
25. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321, 2005
26. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114:1493-1503, 2004
27. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419:316-321, 2002
28. Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948, 2006
29. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028, 2002
30. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634-642, 2005
31. Li X, Monks B, Ge Q, Birnbaum MJ: Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447: 1012-1016, 2007
32. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113-118, 2005
33. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH: PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab 292:E421-E434, 2007
34. van Gorp AG, Pomeranz KM, Birkenkamp KU, Hui RC, Lam EW, Coffer PJ: Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res 66:10760-10769, 2006
35. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43:163-172, 2006
36. Taniguchi CM, Ueki K, Kahn R: Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727, 2005
37. Matsumoto M, Accili D: All roads lead to FoxO. Cell Metab 1:215-216, 2005
38. Adachi M, Osawa Y, Uchinami H, Kitamura T, Accili D, Brenner DA: The forkhead transcription factor FoxO1 regulates proliferation and transdif-ferentiation ofhepatic stellate cells. Gastroenterology 132:1434-1446, 2007
39. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J 3rd, Montminy M: Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449:366-369, 2007
40. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 (Suppl. 3):S53-S55, 2003
41. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122:274-280, 2002
42. Kuningas M, Magi R, Westendorp RG, Slagboom PE, Remm M, van Heemst D: Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur J Hum Genet 15:294-301, 2007